Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article Report
  • Published:

“Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects”

Nature Clinical Practice Oncology volume 5, page E1 (2008)Cite this article

Access through your institution
Buy or subscribe

Arising from: Sanjay Popat and Ian E Smith (2008) Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 5: 324–335 doi:10.1038/ncponc1090

Although optimization of adjuvant therapy reduces the risk of breast cancer recurrence, recognizing and managing the toxic effects caused by such treatment is also important. Cardiac toxicity is an important long-term complication of adjuvant therapy, but most of the recent studies regarding assessment of this adverse effect have a certain number of shortcomings. Assessing the exact quantification of the excess risk of cardiovascular mortality is not straightforward,1 and studies analyzing cardiac toxicity only assess the treatment modalities in isolation (i.e. systemic treatments and radiotherapy). This approach is unable to produce complete data that addresses the effects of each modality in terms of the side effects.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087–2106

  2. Popat S and Smith IE (2008) Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 5: 324–335

    Article  CAS  Google Scholar 

  3. Ryberg M et al. (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100: 1058–1067

    Article  CAS  Google Scholar 

  4. Taylor CW et al. (2007) Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 69: 484–495

    Article  Google Scholar 

  5. Correa CR et al. (2007) Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25: 3031–3037

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Institut Gustave-Roussy, 39, rue Camille Desmoulins, Villejuif, 94805, cedex, France

    Nicolas Magné & Cyrus Chargari

Authors
  1. Nicolas Magné
    View author publications

    Search author on:PubMed Google Scholar

  2. Cyrus Chargari
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Magné.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magné, N., Chargari, C. “Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects”. Nat Rev Clin Oncol 5, E1 (2008). https://doi.org/10.1038/ncponc1275

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/ncponc1275

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing